Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Integrated BioPharma (OTCMKTS:INBP – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.
Volatility and Risk
Enliven Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Enliven Therapeutics and Integrated BioPharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enliven Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Valuation & Earnings
This table compares Enliven Therapeutics and Integrated BioPharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enliven Therapeutics | N/A | N/A | -$71.58 million | ($1.89) | -10.89 |
| Integrated BioPharma | $50.32 million | 0.20 | $110,000.00 | $0.03 | 11.33 |
Integrated BioPharma has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by insiders. Comparatively, 67.2% of Integrated BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Enliven Therapeutics and Integrated BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enliven Therapeutics | N/A | -29.46% | -27.33% |
| Integrated BioPharma | 1.78% | 4.79% | 3.54% |
Summary
Integrated BioPharma beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
